Les Laboratoires Servier
31 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 11 name spellings.
19
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 6 fees due Feb 13 to 25, 2027 · next Feb 13
- 2 fees due Mar 1 to 17, 2027 · next Mar 1
- 1 fee due Apr 22, 2027The maintenance fee for Anti-MET antibodies and compositions (US 10,450,376) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
- 1 fee due May 7, 2027The maintenance fee for Anti-AXL antibodies and compositions (US 11,807,688) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
- 1 fee due Jun 5, 2027The maintenance fee for Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same (US 11,833,162) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 1 fee due Sep 26, 2027The maintenance fee for Combination Therapies Targeting PD-1, TIM-3, and LAG-3 (US 11,939,380) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
- 4 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,867,996 | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it In force · From the USPTO record | In force | From the USPTO record | |
| US 7,479,569 | Process for the synthesis of (7-methoxy-3,4-dihydro-1-naphthalenyl) acetonitrile and its application in the synthesis of agomelatine In force · From the USPTO record | In force | From the USPTO record | |
| US 7,867,994 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid In force · From the USPTO record | In force | From the USPTO record | |
| US 7,960,438 | Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder In force · From the USPTO record | In force | From the USPTO record | |
| US 7,923,569 | β Crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it In force · From the USPTO record | In force | From the USPTO record | |
| US 7,846,961 | α crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it In force · From the USPTO record | In force | From the USPTO record | |
| US 8,414,896 | Recombinant anti-epidermal growth factor receptor antibody compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 7,887,805 | Recombinant anti-epidermal growth factor receptor antibody compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 8,283,294 | Method for cloning cognate antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 8,404,742 | Diosmetin compounds, a process for their preparation and pharmaceutical compositions containing them In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 69: 31 patents in force now held by others · 298 lapsed for an unpaid fee · 172 ended at full term · 1 past the fee grace period · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
23 pending · 13 abandoned · 89 no status recorded